{"id":"W4237480749","doi":"10.2165/00128413-200514870-00042","title":"Health Canada has approved pegaptanib","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pegaptanib; Pharmacy; Family medicine; Internal medicine; Bevacizumab; Ranibizumab","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002276739,0.0001612379,0.0006037931,0.00004596765,0.0001080093,0.00002493614,0.00008455609,0.00004800566,0.0004004762],"category_scores_gemma":[0.0000594282,0.0001331054,0.0001941512,0.000141479,0.00004667853,0.00005916499,0.00001920567,0.0002074222,0.0001054222],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003186938,"about_ca_system_score_gemma":0.001312858,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.154961,"about_ca_topic_score_gemma":0.1213313,"domain_scores_codex":[0.9985936,0.00006163924,0.0003067182,0.0002293556,0.0004142735,0.000394386],"domain_scores_gemma":[0.9990584,0.0001435263,0.00006401033,0.000250658,0.00005225559,0.0004311247],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004255911,0.0003074472,0.03321172,0.0001946859,0.0002612598,0.0009266485,0.0005987866,0.00003771522,0.001111242,0.002081514,0.8188534,0.14199],"study_design_scores_gemma":[0.001438858,0.00006194509,0.03515936,0.00001966322,0.00003367935,0.0003014212,0.00008955604,0.0001630477,0.0003791988,0.000002304695,0.9622164,0.0001345781],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.2698012,0.003000333,0.0001208943,0.643227,0.0006924632,0.0008513134,0.00002793871,0.0002497032,0.08202923],"genre_scores_gemma":[0.9525479,0.00007584487,0.0005819917,0.03072308,0.0006611202,0.00001437983,0.00002399424,0.00002760191,0.01534406],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.6827468,"threshold_uncertainty_score":0.8947021,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02521359520860511,"score_gpt":0.2775660869015151,"score_spread":0.25235249169291,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}